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Abstract
Key roles for connective tissue growth factor (CTGF/CCN2) are demonstrated in the wound repair process where it
promotes myofibroblast differentiation and angiogenesis. Similar mechanisms are active in tumor-reactive stroma
where CTGF is expressed. Other potential roles include prevention of hypoxia-induced apoptosis and promoting
epithelial-mesenchymal transistion (EMT). CTGF expression in tumors has been associated to both tumor
suppression and progression. For example, CTGF expression in acute lymphoblastic leukemia, breast, pancreas and
gastric cancer correlates to worse prognosis whereas the opposite is true for colorectal, lung and ovarian cancer.
This discrepancy is not yet understood.
High expression of CTGF is a hallmark of ileal carcinoids, which are well-differentiated endocrine carcinomas with
serotonin production originating from the small intestine and proximal colon. These tumors maintain a high grade
of differentiation and low proliferation. Despite this, they are malignant and most patients have metastatic disease
at diagnosis. These tumors demonstrate several phenotypes potentially related to CTGF function namely: cell
migration, absent tumor cell apoptosis, as well as, reactive and well vascularised myofibroblast rich stroma and
fibrosis development locally and in distal organs. The presence of CTGF in other endocrine tumors indicates a role
in the progression of well-differentiated tumors.
Background
It is well established that connective tissue growth factor
(CTGF/CCN2) is a key component in wound repair.
A consensus for the role of CTGF in tumorigenesis, how-
ever, has been surprisingly difficult to reach despite studies
in many tumor types and cell-lines. Directly opposing
effects have been demonstrated in different tumor types
and even within the same tumor diagnosis (summarized in
Table 1). This review provides a brief summary of our cur-
rent knowledge and treats possible explanations for discre-
pancies between studies. Extra focus will be given to ileal
carcinoids, which express high levels of CTGF, as their
unique phenotype and tumor behavior may provide a
model for understanding CTGF function.
CTGF in development
Tissue-specific developmental programs are often reacti-
vated in solid tumors and understanding CTGF’sr o l ei n
development may be relevant to its role in tumorigenesis.
CTGF knockout mice die at birth due to skeletal defects
in the ribcage that impair respiration [1]. This phenotype
is thought to involve impaired chondrocyte proliferation
and disturbed angiogenesis. Interestingly, null embryos
also have abnormal pancreatic islet morphology. Specifi-
cally, they display higher numbers of glucagon positive
cells and fewer insulin positive cells. The CTGF heterozy-
gotes survive past birth and exhibit generally alpha- and
beta-cell hypertrophy which indicates that CTGF may be
involved in the establishment of normal islet endocrine
cell ratio and architecture butt h e i rg r o s sa p p e a r a n c ei s
otherwise normal [2,3]. A nine-fold overexpression of
CTGF in transgene mice causes abnormalities, including
developmental delay and craniofacial defects, and
embryonic death but an overt fibrotic phenotype was not
seen [3].
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modifications
CTGF is a 349-amino acid polypeptide consisting of four
domains (see Figure 1A). Full length CTGF has an esti-
mated molecular weight of 33 kD while cleavage in the
hinge region produces N- and C-terminal fragments with
an estimated molecular weight of 20-23 kD and these
fragments may have specific biological functions [4,5].
Different cellular sources may offer different proteases
for CTGF processing, thus forming a subset of fragments,
which in turn determines CTGF action. It is speculated
that CTGF may even promote its own proteolysis in
some tissues, resulting in differential retention of a speci-
fic fragment [6]. High levels of N-terminal CTGF are
found in patients with fibrotic scleroderma [7] and in dia-
betic patients with nephropathy [8].
In vitro studies demonstrate that N-terminal CTGF
mediates TGF-b induced myofibroblast differentiation by
upregulating expression of alpha-smooth muscle actin
(a-SMA) and collagen. In the same study, in the presence
of C-terminal CTGF, proliferating fibroblast were
observed, which neither express a-SMA nor produce col-
lagen [4]. This study also indicates that the presence of
other growth factors, such as EGF, IGF-I and II and
TGF-b, may influence the degree to which these different
fibrotic processes are active [9].
In vivo, full length CTGF is often glycosylated and this
increases the molecular weight from 33 kD to 42 kD or
more. This glycosylation may be important for function.
For example, in a renal fibroblast cell line, overexpression
of CTGF results in growth arrest, whereas exogenously
added recombinant CTGF increased proliferation [10].
Methods
We aimed to examine the role of CTGF in tumorigen-
esis. Medline articles, other reviews and citation lists in
relevant articles were searched for studies on CTGF’s
expression in human tumor specimens, primary human
tumor cell cultures, knock-out mice and normal tissue
(see supplement for search terms). Articles were pub-
lished between the years 1997-2010. Studies that only
showed results from cell lines were excluded. CTGF
expression in tumors tissue was compared to normal tis-
sue. Studies were sorted according to the cancer type
and endocrine phenotype and according to reported
CTGF correlation to tumor progression.
Results
CTGF in tumorigenesis
CTGF’s role in tumor development can be divided into 3
categories seen in additional file 1: tumor promotion, sup-
pression or both (complex). There appears to be a rela-
tionship between CTGF’s role and its basal expression in
the original normal cell or non-transformed tissue. Group
A tumors, which includes breast and pancreas cancer have
a positive correlation between CTGF and tumor develop-
ment – higher levels of CTGF are expressed in metastases
and CTGF is correlated to later tumor stages. The normal
cell counterparts of these tumors are not found to express
C T G F .C T G Fi sn o r m a l l ye x p r e s sed in endothelial cells,
fibroblasts, smooth muscle cells and myofibroblasts, and
some epithelial cell types in diverse normal tissues [11].
Group B tumors, which include chondrosarcoma [12] and
lung cancer [13], are formed from cell types, which are
reported to express CTGF and are often reported to have
Figure 1 A: Full length CTGF contains 4 modules: insulin-like growth factor binding protein-like (IGFBP), von Willebrand factor type-C
repeat (VWF), thrombospondin type 1 repeat (TSP-1) and C-terminal cystine knot (cys-knot). Arrows indicate potential cleavage sites. B:
Ileal carcinoid tissue immunostained with antibodies to CTGF (A), a-SMA (B) and CD31/CD34 (C) identifies vascular endothelial cells)
demonstrating typical tumour cell IR for CTGF and stromal expression of a-SMA detected both in myofibroblasts and in vascular smooth muscle
cells.
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sion and malignant phenotype (Additional file 1).
The complicated nature of CTGF in tumor progression
is evident in the group C tumors. In ovarian cancer, for
example, CTGF is normally expressed in apical cytoplasm
of normal ovarian epithelial cells. Gene methylation and
reduced expression, in relation to normal cells, of CTGF is
frequently observed in primary ovarian cancer tissues.
High CTGF expression in early stage ovarian tumors
appears to have a protective effect procuring prolonged
survival but this must be verified in a larger cohort. In
vitro studies on a panel of ovarian cancer cell lines support
CTGF’s putative tumor growth suppressive effect: in cells
lacking CTGF, both exogenous restoration of expression
and treatment with recombinant CTGF inhibited prolif-
eration while knockdown of CTGF in cells with endogen-
ous expression accelerated proliferation [14]. Surprisingly,
CTGF expression is often restored in the most advanced
tumor stages of ovarian cancer and is correlated to a more
malignant phenotype [14].
Factors other than CTGF differ between the tumor
groups. These factors may include the presence of other
growth factors and posttranscriptional modifications of
CTGF.
CTGF as a tumor promoter
Several potential functions for CTGF in tumor develop-
ment in the group A tumors involve both direct action on
the tumor cells and modification of tumor microenviron-
ment. CTGF, in this manner, encourages tumor invasion,
cell survival and angiogenesis.
Metastases formation requires that the cell detach from
the matrix and adopt cytoskeltal changes reminiscent of
mesenchymal cells. Normally, detachment from ECM
results in cell death, which must also be avoided for
tumor development. The process of epithelial to
mesenchymal transition (EMT), seen during embryonic
development, describes the process where epithelial cells
acquire a mesenchymal cell phenotype, which is more
prone to migrate and invade. EMT is also thought to be a
key component in both malignant epithelial tumor pro-
gression [15] and fibrotic diseases [16]. Transforming
growth factor-beta (TGF-b), and downstream mediators
including CTGF are major initiators of EMT processes in
both fibrosis [16] and cancer progression [17]. These pro-
cesses may be independent from each other as a TGF-b
and CTGF-dependent induction of EMT was indepen-
dent of the profibrotic effects of TGF-b in proximal tubu-
lar cells [18]. CTGF has been implicated in other
processes requiring cell migration such as the reepithelia-
lisation in corneal epithelial cells, which is mediated
through TGF-b and CTGF signaling, with downstream
ERK1/2 and p38 MAPK activation [19].
A central part of CTGF’s role in endothelial cell func-
tion and angiogenesis may involve direct interaction
with integrins in mediating cell migration and to avoid
cell death. Integrins anchor cells to the extracellular
matrix and are involved in defining cell shape and moti-
lity and are even implicated in regulating cell cycle.
CTGF stimulates integrin expression and is shown to
bind directly to endothelial cell surface integrins [20,21]
to mediate ECM interaction and prolonging cell survi-
val. CTGF mediates anchorage-independent cancer cell
growth and support for this is based on findings where
anti-CTGF treatment inhibits anchorage-independent
growth in vitro, primary tumor growth in vivo and
macroscopic lymph node metastases [22].
CTGF is capable of up-regulating both matrix metallo-
proteinases (MMPs) and their inhibitors (tissue inhibitor
of metalloproteinases, TIMPs) and has the potential to
activate both the synthesis and degradation of the extra-
cellular matrix. Some tumors involve a desmoplastic
reaction, a process that closely resembles chronic fibro-
proliferative disease that may serve to protect tumor
cells from immune detection and chemotherapy. CTGF
involvement in this process has been demonstrated in
pancreatic cancer [23].
Hypoxia is a strong inducer of CTGF expression. CTGF
co-localizes with hypoxia marker CAIX and the CTGF
promoter contains a recognition site for hypoxia growth
factor, HIF [23,24]. In several systems, CTGF protects
from hypoxia-induced apoptosis allowing tumor growth
despite hypoxia [11,25]. The prolonged cellular survival
may be mechanistically similar to CTGF treatment of
mesangial cells, which leads to rapid activation of ERK1/2
and reduced phosphorylation of Bcl-2 promoted cell survi-
val [26]. CTGF protects from hypoxia-induced apoptosis
[23] and is a strong stimulator of angiogenesis [11]. In
contrast, some studies have reported CTGF to induce
tumor cell apoptosis but it has been argued that this may
be due to either overexpression or very high doses of the
protein [6].
CTGF as a tumor suppressor
In some tumors (group B), CTGF may act as a tumor sup-
pressor gene. In these cases, CTGF is often expressed in
the normal cells and its expression decreases with the
grade of malignancy. CTGF action in some tumors is also
in sharp contrast to what is seen in others. For example, in
lung cancer, CTGF appears to be acting through inhibition
of phosphorylation of ERK1/2 [13,14,27]. CTGF induced
suppression of ERK1/2 phosphorylation is also seen in
ovarian cancer cells (Group C) [14]. In breast cancer cells
(group A), however, CTGF activates ERK1/2 phosphoryla-
tion [28]. The b-catenin pathway also appears to react in
opposite directions to CTGF stimulation in the different
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CTGF, b-catenin and cell migration is noted between
tumors in the groups. For example, decreasing CTGF
levels by silencing RNA in colorectal cancer cells (group
B) increases their invasive ability and metastatic capacity
in mice and over-expression of CTGF decreases b-cate-
nin/T-cell factor signaling [29]. In esophageal carcinoma
cells (group C), however, CTGF over-expression gave
increased tumor formation in mice and this is shown to be
via increased b-catenin/T-cell factor signaling [30].
The role of CTGF in endocrine tumors
Endocrine tumors are rare hormone producing tumors
derived from endocrine cells in many different organs in
the body. Their common endocrine nature is the reason
they are often grouped for study. They display, however,
wide variations in symptoms, malignant potential and
tumor biology and are classified according to the WHO
classification scheme which sorts tumors according to pri-
mary tumor site, metastases development, hormone pro-
duction and proliferation [31]. Our studies on CTGF
expression in these tumors have identified clear differences
in CTGF expression (See Additional file 1, group D).
CTGF in ileal carcinoids
Ileal carcinoids, also known as midgut carcinoids, are sero-
tonin producing endocrine tumors found in the small
intestine and proximal colon. These tumors are particular-
ity interesting as they ubiquitously express very high levels
of CTGF [32] and provide a platform for understanding
CTGF function. Ileal carcinoids demonstrate several phe-
notypes potentially related to CTGF, namely: high level of
cell migration, a reactive and well vascularised myofibro-
blast rich stroma and fibrosis development locally as well
as in distal organs.
Ileal carcinoids have a pronounced association with
fibrosis development [33-35]. Fibrosis caused by associated
factors is emerging as a major issue in the morbidity and
mortality of the disease [36,37]. Complications related to
fibrosis arise in 16-48% of patients [35]. Tumor produced
hormones, serotonin [38-41] and tachykinins [42-44], have
been shown to be related to fibrosis. Growth factors such
as PDGF, IGF-I, EGF, TGF-a and TGF-b and their recep-
tors have also been discussed in the context [35,45-50].
TGF-b induced fibroblast proliferation, collagen synthesis
and myofibroblast differentiation is mediated by CTGF
dependent pathways [9,51,52]. Our work demonstrates
that while myofibroblasts were found in various types of
endocrine tumors, ileal carcinoids displayed exceptionally
high proportion of a-SMA immunoreactive fibroblast-like
cells in an extensive stroma.
The association between serotonin and CTGF is evident
in the literature. Serotonin induction of CTGF expression
in renal mesangial cells is accompanied by activation of
serotonin receptor 5HT2A [53]. Serotonin is also
implicated in CTGF induction in hepatic stellate cells and
may have a function in the development of liver fibrosis
[54]. A recent study in the KRJ-1 cell-line (derived from
ileal carcinoid tumor) demonstrated that 5HT2B receptors
are highly expressed in these cells compared to normal
enterochromaffin cells. Blocking 5HT2B receptors with
specific antagonists decreased ERK1/2 phosphorylation,
reduced serotonin secretion, TGF-b, CTGF and FGF2
transcription and reduced proliferation [55]. Serotonin
administration induces heart valve fibrosis that resembles
carcinoid heart disease in rats through induction of TGF-b
and CTGF in the heart smooth muscle [39]. Full length
CTGF can be found in patient serum and is potentially
involved in carcinoid associated fibrotic disease [56].
Ileal carcinoids maintain a high grade of differentiation
and low proliferation. Despite this, they are truly malig-
nant; most patients have metastatic disease at diagnosis
and those who initially undergo “radical” surgery are fre-
quently (50-80%) diagnosed with metastatic recurrence
within 5-15 years [57-59]. There is no capsule surrounding
the primary tumor, instead the tumor is comprised of
small tumor clusters that often appear to spread laterally
along the basal membrane and infiltrate the muscle layers.
The histopathological appearance supports the hypothesis
that cell migration is an early event in tumor development.
CTGF is, as discussed earlier in the text, involved in both
cell migration and EMT. It is feasible that the malignant
behavior seen in ileal carcinoids may be in some ways
related to the high degree of CTGF expression.
It is generally presumed that ileal carcinoids are derived
from serotonin producing enterochromaffin (EC) cells in
the small intestine. Using double staining techniques, we
have recently shown that while EC cells in the stomach
are CTGF negative, both CTGF-positive and negative
fractions of EC cells are found in the intestine [60]. The
function of CTGF in intestinal EC cells is unknown and
may hold clues for understanding ileal carcinoid biology.
CTGF in enterochromaffin-like cell carcinoids
While the enterochromaffin-like cell carcinoids (ECL-
CCs) displayed CTGF expression far lower than the ileal
carcinoids, we were intrigued by the variation in expres-
sion between different types of ECL-CCs and the finding
that CTGF immunoreactivity was strongest in tumor
cells facing the fibrovascular stroma. CTGF expression is
absent in normal enterochromaffin-like (ECL) cells and
in foci of ECL-like cell hyperplasia. CTGF expression
shows up first in the type I ECL-CCs larger than 5 mm,
and its expression was correlated with a tumor size >1
cm. CTGF immunoreactivity in large type I ECL-CCs
may be related to hypoxia, which occurs when tumor size
exceeds the distance oxygen can diffuse into the tissue.
CTGF is induced by hypoxia and is known to be a potent
angiogenic factor (see above). CTGF and advanced tumor
stage in well-differentiated ECL-CCs correlated but no
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results suggest that CTGF may be involved in initiating
or promoting the neoplastic process. CTGF expression
was absent in gastric poorly differentiated endocrine car-
cinomas (PDECs), and this may imply that CTGF is
mainly involved in early pathogenesis becoming less
important in the presence of further genetic aberrations
and loss of differentiation.
CTGF is not correlated to proliferation in ileal carci-
noids whereas, in ECL-CCs, the correlation between
CTGF expression and Ki-67 proliferative index is negative
[32,60]. We hypothesize that CTGF expression in well-dif-
ferentiated tumors, in addition to proposed tumor promo-
tion effects, has a simultaneous function in maintaining
the low proliferative and differentiated phenotype. Loss of
CTGF expression in more advanced, anaplastic stages
supports this.
CTGF in endocrine tumors - concluding comments
Our observations can be summarized as follows; CTGF is
highly expressed in a subgroup of well-differentiated endo-
c r i n et u m o r s .I nt h e s et u m o r s ,proliferation is generally
low and the endocrine phenotype is apparent. CTGF is
often, but not always, in conjunction with serotonin pro-
duction and in cases where high expression of both is pre-
sent, extensive myofibroblast-rich stroma is found.
Abundant expression of CTGF in some tumor types
seems to correlate with increased size and tumor stage.
We believe that CTGF may be involved in early neoplastic
processes that allow for advanced tumor stage and metas-
tases development. In contrast to this, CTGF expression
in the highly proliferative, PDEC is most often lost [32,60].
CTGF expression in normal endocrine cells has not been
systematically studied in all organs. Our results in endo-
c r i n et u m o r si n d i c a t eac o m p l ex relationship between
CTGF and tumor progression but should be verified in
other tumor cohorts. For these reasons, we have chosen
not to place these tumors in the categories A-C but in a
separate group, D, until there is enough data for these
tumors to be sorted with certainty.
CTGF as a treatment target
Regulating the TGF-b pathway has long been a goal for
treatment of both cancer and fibrotic disease. TGF-b sig-
naling is however more complicated than initially thought
and strategies that block downstream events in the cas-
cade may offer more selective effects. CTGF is potentially
an important therapy target. Our understanding of its
functions is still in the early stages and more knowledge is
needed about its processing in vivo to reliably predict its
function in vivo. CTGF has been shown to bind several
receptors but there is to date no known CTGF-specific
receptor.
R e s u l t sf r o ma n i m a lm o d e l so fc a n c e rw h e r eC T G F
signaling is blocked have shown promise. CTGF-specific
antibodies (FG-3019) inhibit pancreatic tumor growth
and metastasis in nude mice [22] as well as in an ortho-
topic mouse model [61]. The main anti-tumoral effects
were increased tumor cell apoptosis and attenuated
angiogenesis. Clinical trials using FG-3019 in patients
with pancreas cancer are now initiated. Another
approach involves a DNA vaccine consisting of a combi-
nation of CTGF and viral tumor antigen E7 DNAs. This
vaccine was shown to generate T-cell mediated antitu-
mor immune response in a mouse cervical cancer [62].
Synergistic benefits of combining the CTGF DNA vac-
cine in combination with chemotherapy is reported
where antitumor effects included inhibition of angiogen-
esis [63].
The potential tumor suppressive effect of CTGF should
not, however, be forgotten. Based on our current under-
standing, there is a risk that treatment which results in
down regulation of CTGF may also remove its simulta-
neous tumor suppressive effects. Under this concept, there
is an additional risk of stimulating development or pro-
gress of an additional tumor in another organ where
CTGF has a tumor suppressive effect. This risk may be a
limiting factor when deciding to treat other tumor forms
with better prognosis than pancreas cancer.
Conclusions
CTGF in the context of cancer is a clearly intriguing mole-
cule and a potential candidate for therapeutic targeting.
A full characterization of its regulation, in particular,
understanding the determinates of its opposite actions in
different cell-lines and cancer types is essential for predict-
ing and preventing paradoxal tumor reactions.
Additional material
Additional file 1: Summary of current knowledge concerning CTGF
expression in tumors and corresponding normal tissues in relation
to tumor progression (SEE Additional File 2).
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